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Intraperitoneal Injection Is Not Always a Suitable Alternative
to Intravenous Injection for Radiotherapy
Shuping Dou, Miles Smith, Yuzhen Wang, Mary Rusckowski, and Guozheng Liu
Abstract
Intraperitoneal (IP) injection is frequently reported to be as effective as intravenous (IV) injection. Because it
allows administering a larger volume with more radioactivity, we have investigated this route and the possi-
bility of using it to circumvent the volume constraint we earlier experienced with pretargeting radiotherapy.
Using 99mTc as the label, the pharmacokinetics (PK) of the cMORF effector (a DNA analogue) was evaluated
after IP or IV injection in normal mice by necropsy and SPECT/CT imaging. In another experiment, nude mice
bearing tumors were used and they received MORF-CC49 pretargeting antibody IV 2 days earlier than labeled
cMORF IV or IP. Tumor accumulations of cMORF were measured at 6 hours after its injections. The absorbed
radiation doses for 188Re or 90Y pretargeting were estimated using the 99mTc data and a self-absorbed model.
Although the absorbed radiation doses to other organs were comparable, the dose to intestines after IP injection
was 30-fold higher than IV injection due to the slow entry into the circulation. It had reached such a level as high
as the dose to the kidneys that cleared the radioactivity and usually were at the highest level. Nevertheless, the
slow entry did not reduce the tumor accumulation. In conclusion, using IP in place of IV led to an unacceptably
high absorbed radiation dose to the intestines although the tumor accumulation was not compromised. This
effect may be applicable to other radiotherapeutic agents as well.
Key words: absorbed radiation dose, biodistribution, intraperitoneal, intravenous, pretargeting, tumor
accumulation
Introduction
Intravenous (IV) and intraperitoneal (IP) injections weretwo most widely used administration routes. IP was often
considered to be an effective route for tumor therapy1–5, al-
though it was not as commonly used as IV. Some studies even
concluded IP was slightly preferable,6,7 although it was
occasionally thought to be inferior.8 During our previous in-
vestigations on tumor therapy by MORF/cMORF pretarget-
ing (a pretargeting strategy using a recognition pair of DNA
analogues, MORF/cMORF), the dose escalation of radi-
olabeled cMORF was constrained by its injection volume.9,10
If IP were as effective as IV, this volume constraint could be
easily lifted, because IP injection (i.e., the IV + IP combination
in Fig. 1) could allow a much larger volume. Thus, in a pilot
study, we tested a high radioactivity dose of 188Re-cMORF
by IP injection but observed intestinal radiotoxicity, including
diarrhea, partial mortality in the group, and the appearance of
loose intestinal walls after dissection of the remaining eutha-
nized sick animals (data not presented).
Suspecting that the radiotoxicity involved long duration of
radioactivity in the peritoneal cavity after IP injection, we
designed this investigation to examine the kinetic difference
and the absorbed radiation doses to organs after IP and IV.
Most IP studies in the literature considered bioavailability
and therapeutic effect.1–8 When radiotoxicity to organs was
considered, intestines were rarely included, probably due to
the lack of a method to accurately measure the radioactivity
in the peritoneal cavity. In this investigation, we have de-
signed such a method, applied to our MORF/cMORF pre-
targeting, and compared the absorbed radiation doses to
organs including the intestines between IP and IV. The 99mTc
was used as the label in place of 188Re or 90Y to measure the
pharmacokinetics (PK) of the labeled cMORFs, because
Department of Radiology, University of Massachusetts Medical School, Worcester, Massachusetts.
Address correspondence to: Guozheng Liu; Division of Nuclear Medicine, Department of Radiology, University of Massachusetts Medical
School; 55 Lake Avenue North, Worcester, MA 01655-0243
E-mail: guozheng.liu@umassmed.edu
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
Volume 28, Number 4, 2013
ª Mary Ann Liebert, Inc.
DOI: 10.1089/cbr.2012.1351
335
previous observation indicated that PK was essentially in-
dependent of the labels.11
Experimental Section
The base sequences of MORF and cMORF were the same
as previously reported12 and they were from Gene-Tools
(Philomath, OR). The cMORF was conjugated with NHS-
MAG3 for
99mTc labeling.13 The anti-TAG-72 CC49 antibody
was custom produced by Strategic Biosolutions (Ramona,
CA) from the CC49 hybridoma (a gift from Dr. Jeff Schlom,
Center for Cancer Research, NCI, NIH). It was conjugated
with MORF using a commercial Hydralink approach.14,15
The 99Mo-99mTc generator was from Perkin Elmer Life Sci-
ence, Inc. (Boston, MA). All other chemicals were reagent
grade and used without purification.
The concentrations of MORF, cMORF, and antibody were
determined by UV spectrophotometry. Size exclusion high
performance liquid chromatography (HPLC) was used for
their analysis. The HPLC system was equipped with a Su-
perdexTM 75 column (optimal range: 3–70 kDa) or a Super-
ose-12 column (optimal range: 1–300 kDa) from Amersham
Pharmacia Biotech (Piscataway, NJ), an in-line UV detector,
and an in-line radioactivity detector. The eluant was a 0.10 M
phosphate buffer at pH 7.2 running at a flow rate of 0.60 mL/
minute. Radioactivity recovery was routinely measured and
was always greater than 90%.
All animal use was in accordance with the guidelines of
the Animal Care and Use Committee of the University of
Massachusetts Medical School and conformed to the rec-
ommendations in the Guide for the Care and Use of Laboratory
Animals (Institute of Laboratory Animal Resources, National
Research Council, National Academy of Sciences, 1996). The
normal CD-1 mice were from Charles River (Wilmington,
MA) and the NIH Swiss nude mice were from Taconic Farms
(Germantown, NY).
Peritoneal adsorption and PK of labeled cMORF
As cMORF entered the circulation more slowly by IP than
by IV, the study was designed to be different. For IV, after
the normal mice in the six groups (n = 3) each received
0.10 mL of radiolabeled cMORF (1lg, 100 lCi), they were
euthanized at six time points of 2, 10, 30 minutes, 1, 2, and 3
hours by chest opening and heart puncture under isoflurane
anesthesia. Organs were harvested and routinely counted
along with the injectate as standard. For IP, the observation
period was longer and seven groups of mice were eutha-
nized at 2, 30 minutes, 1, 2, 3, 4, and 6 hours. The injection
volume of the labeled cMORF was 10-fold larger (1.0 mL)
although the injected mass and radioactivity were the same.
A procedure was performed to measure both the radio-
activity (X) and fluid volume (V) in the peritoneal cavity
after IP injection before organ collection. Specifically, an
aliquot (Y1= 2 mL) of isotonic phosphate buffered saline so-
lution containing 0.05% human serum albumin (diluting
buffer) was injected into the cavity. Following gentle palpi-
tations of the abdominal region to effect uniform dilution of
the radioactivity in the cavity, a small volume (S1= 0.2 mL)
was sampled. Then, a second set of buffer injection (Y2) and
sampling (S2) was applied. Finally, the solution in cavity was
all withdrawn and the cavity was opened. The organs in
cavity were washed with the diluting buffer after excision
and the liquid samples (S1 and S2) were counted together
with the solid organs to provide the radioactivity concen-
trations (C1 and C2 in lCi/mL). From the principle of con-
servation of radioactivity (decay corrected)
X¼ (Y1þV) ·C1; X S1 ·C1¼ (Y1þY2þV S1) ·C2 (1)
the following equations were derived to calculate the cavity
radioactivity and fluid volume:
X¼
Y2 S1þ S1

C1
C2

C 12 C 11
;V¼ X
C1
Y1 (2)
The distribution of radioactivity over the body was visu-
alized by imaging with a small animal SPECT/CT camera
(Bioscan, Washington, DC). Higher specific radioactivity
(1 lg, 370– 10lCi) was injected to each of the mice in two
groups (n = 4) to facilitate imaging. Because the biodistribu-
tion was changing rapidly, especially after IV injection, the
imaging was performed after euthanasia. The euthanization
times were 2 minutes, 0.5, 1.0, and 1.5 hours and the imaging
conditions were identical (24 projections at 60s/projection).
In the end, the radioactivity left in the whole body was
measured using a dose calibrator.
Tumor accumulations in pretargeted nude mice
For tumor accumulation, under the condition that the
binding sites were not saturated, we had previously pro-
vided an expression (named MPTA)16,17:
MPTA¼ F· f ·W  1 ·E ·
ðt¼1
t¼ 0
C(%ID=g)blood · dt
¼ F· f ·W  1 ·E ·AUC of %ID=g
(3)
where F was the cardiac output; f was the fraction of the
cardiac output reaching tumor; W was the tumor weight; E
was the tumor trapping fraction of effector. Based on this
expression, as F, f, W, and E were the same for IP and IV in
this investigation, the ratio of the MPTA by IP over IV should
be the ratio of the AUC of %ID/g of blood. By definition,18
this ratio was the bioavailability of cMORF after IP injection:
FIG. 1. Two combinations of the
injection routes (intravenous [IV] +
IV and IV + Intraperitoneal [IP]) for
pretargeting radiotherapy. MORF is
a phosphorodiamidate morpholino
oligomer (a DNA analogue).
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MPTAIP
MPTAIV
¼
AUC of %ID=g
IP
AUC of %ID=g
IV
¼Bioavailability by IP (4)
The blood radioactivity–time curve should essentially be
the same with and without pretargeting. Therefore, the AUC
of %ID/g from the normal mice were used for the pretargeted
mice. Based on the measured bioavailability (as will be
shown, is 96%), the tumor accumulations after IP and IV
injections were predicted to be the same by formula (4).
To confirm this prediction, the MPTAs were measured
using 8 Swiss NIH nude mice. Each was inoculated in the left
thigh with 106 LS174T colon tumor cells. After 12 days when
tumors were about 0.2 g, 15lg of MORF-CC49 (MORFs/
antibody = 1.5) was injected IV. Two days later, 2lg (80lCi)
of 99mTc-cMORF in 0.1 mL was injected IV to each of the four
in one group, while the same amount of labeled cMORF in
1 mL was injected IP to each of the other four. All the mice
were euthanized for biodistribution at 6 hours, a time point
when the radioactivity had cleared from circulation even for
IP injection. Organs and tumor were routinely collected for
the radioactivity counting as previously described.12
Absorbed radiation doses to blood, kidney,
and intestines
Because of the minimal influence of radiolabel and
pretargeting antibody on the normal organ accumulations
of cMORFs11, biodistribution data for the 99mTc-cMORF in
normal mice was used to estimate the absorbed radiation
doses (Rad) to organs of interest for the pretargeting
therapy using 188Re- or 90Y-cMORFs. To calculate the ab-
sorbed radiation dose to the intestines, the sum of the ra-
dioactivity in cavity fluid and the intestinal radioactivity
(total cavity radioactivity) was used. For an injection dose
of 100 lCi, the areas under the radioactivity curves (AUCs)
were calculated after converting the %ID- or %ID/g-time
curves to the decay corrected lCi-time curves (17.0 hours
for 188Re and 64.0 hours for 90Y). As before, the self-ab-
sorbed model was utilized for the dosimetry using the
formula of 2.143* Eb*AUC (lCi*h)/W(g) or 2.143* Eb*AUC
(lCi/g*h),9,10 where 2.143 was a unit conversion factor,
Eb was the average electron energy (MeV), and W was
the organ weight (for intestines, the content was also
included).
Table 1. Pharmacokinetics of 99mTc-cMORF in Normal Mice After IP and IV Injections. N = 3; Mean – SD
(a) Intraperitoneal
%ID/g 2 minutes 30 minutes 1 hour 2 hours 3 hours 4 hours 6 hours
Liver 0.16 – 0.04 0.21 – 0.00 0.22 – 0.06 0.29 – 0.01 0.16 – 0.04 0.41 – 0.21 0.20 – 0.01
Heart 0.07 – 0.02 0.19 – 0.02 0.19 – 0.01 0.16 – 0.01 0.14 – 0.02 0.07 – 0.02 0.04 – 0.00
Kidney 0.33 – 0.03 2.19 – 1.21 3.68 – 1.70 3.15 – 0.28 3.60 – 0.69 4.55 – 1.41 3.19 – 0.37
Lung 0.08 – 0.03 0.36 – 0.01 0.29 – 0.03 0.27 – 0.04 0.28 – 0.07 0.13 – 0.06 0.08 – 0.01
Spleen 0.20 – 0.03 0.24 – 0.03 0.19 – 0.02 0.29 – 0.01 0.14 – 0.02 0.22 – 0.09 0.15 – 0.02
Muscle 0.03 – 0.03 0.09 – 0.03 0.10 – 0.01 0.10 – 0.01 0.07 – 0.01 0.04– 0.01 0.02 – 0.00
Pancreas 0.49 – 0.20 0.33 – 0.01 0.43 – 0.09 0.43 – 0.05 0.22 – 0.01 0.35 – 0.13 0.25 – 0.04
Blood 0.27 – 0.07 0.72 – 0.04 0.61 – 0.09 0.60 – 0.08 0.49 – 0.06 0.13 – 0.04 0.04 – 0.01
%ID/organ
Stomach 0.14 – 0.14 0.14 – 0.03 0.24 – 0.01 0.22 – 0.05 0.13 – 0.01 0.39 – 0.11 0.09 – 0.01
Small intestine 0.21 – 0.02 0.44 – 0.03 1.21 – 1.13 0.60 – 0.18 0.59 – 0.21 0.47 – 0.13 0.09 – 0.01
Large intestine 0.09 – 0.02 0.12 – 0.01 0.17 – 0.07 0.79 – 0.21 0.97 – 0.39 1.12 – 0.25 0.24 – 0.04
Cavity 93.1 – 5.55 71.8 – 5.3 58.9 – 13.2 34.8 – 6.9 16.2 – 4.3 0.52 – 0.20 0.10 – 0.09
Volume or mass
Cavity fluid (mL) 1.43 – 0.21 1.52 – 0.29 1.42– 0.28 1.08 – 0.13 0.75 – 0.18 0.72 – 0.45 0.37 – 0.21
Intestines (g) 2.60 – 0.90 2.77 – 0.08 2.87 – 0.43 3.03 – 0.19 3.60 – 0.43 3.27 – 0.07 3.10 – 0.26
IP, intraperitoneal; IV, intravenous.
(b) Intravenous
%ID/g 2 minutes 10 minutes 30 minutes 1 hour 2 hours 3 hours
Liver 2.42 – 0.36 0.80 – 0.09 0.31 – 0.05 0.23 – 0.05 0.22 – 0.02 0.18 – 0.02
Heart 4.14 – 0.36 1.25 – 0.10 0.28 – 0.11 0.11 – 0.03 0.06 – 0.01 0.04 – 0.01
Kidney 39.2 – 6.5 11.2 – 0.90 6.51 – 1.85 3.97 – 0.69 4.98 – 0.48 4.00 – 0.73
Lung 7.13 – 0.72 2.52 – 0.18 0.68 – 0.11 0.24 – 0.05 0.17 – 0.05 0.09 – 0.00
Spleen 1.66 – 0.13 0.63 – 0.06 0.21 – 0.06 0.10 – 0.03 0.09 – 0.02 0.05 – 0.00
Muscle 1.64 – 0.05 1.10 – 0.04 0.28 – 0.09 0.09 – 0.02 0.05 – 0.02 0.03 – 0.00
Pancreas 3.55 – 0.33 1.39 – 0.24 0.43 – 0.14 0.28 – 0.04 0.09 – 0.01 0.06 – 0.01
Blood 14.2 – 1.8 3.68 – 0.31 0.83 – 0.27 0.24 – 0.08 0.04 – 0.00 0.02 – 0.00
%ID/organ
Stomach 0.86 – 0.08 0.40 – 0.01 0.15 – 0.05 0.09 – 0.03 0.06 – 0.02 0.15 – 0.09
Small intestine 4.13 – 0.14 1.68 – 0.12 0.82 – 0.16 0.78 – 0.01 0.57 – 0.16 0.17 – 0.04
Large intestine 1.41 – 0.14 0.62 – 0.08 0.16 – 0.05 0.13 – 0.04 0.23 – 0.19 0.62 – 0.02
Mass
Intestines (g) 2.86 – 0.26 2.99 – 0.25 2.77 – 0.29 2.78 – 0.26 2.56 – 0.10 2.91 – 0.28
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Results
Peritoneal adsorption and PK of labeled cMORF
Table 1 lists the radioactivity amount and fluid volume in
the peritoneal cavity after IP injection along with the radio-
activity accumulations in normal organs after both IP and IV
injections. The peritoneal fluid sampling method in this re-
port has been confirmed to provide the same radioactivity
value as that by rinsing out the radioactivity completely
(data not presented) but with an advantage to provide the
fluid volume in addition.
The radioactivity curves for the organs of interest are re-
produced in Figure 2. Interestingly, the labeled cMORF en-
ters into the circulation more rapidly than its host buffer (Fig.
2A). In addition, the 2-minute fluid volume is 1.6 mL, that is,
by about 0.6 mL larger than the originally injected 1.0 mL
likely due to the hypertonicity of the labeling buffer (the total
concentration of monocations is about 0.27 M, i.e., 1.7-fold of
that in the isotonic saline). Figure 2B shows that after IP
injection the labeled cMORF enters into blood and clears
within 4–6 hours as compared with 1–2 hours after IV in-
jection. As an example of normal organs, the curve for the
lung is shown in Figure 2C. After IP injection, the accumu-
lation slowly increases, gets over a peak of much lower
height, and slowly clears in parallel with the blood level.
Figure 2D demonstrates the radioactivity accumulations in
the kidney, with a feature that the two lines merge at a level
of about 4%ID/g instead of at the bottom.
The slower entry of the labeled cMORF into the circulation
after IP injection can be visually appreciated by consulting
the SPECT/CT images (Fig. 3). Within the first 1.5 hours after
IP injection, consistent to the necropsy data in Table 1 and
Figure 2A, the radioactivity in the peritoneal cavity domi-
nates the image. Radioactivity in bladder becomes visible at
30 minutes and increases with time. Radioactivity in other
organs including kidneys is relatively low as compared with
that in the cavity, such that the signals are overwhelmed. For
IV, the clearance essentially completes within 30 minutes as
shown in the lower row. Apart from the bladder, only kid-
neys are visible thereafter.
Tumor accumulations in pretargeted nude mice
The bioavailability of 99mTc-cMORF (i.e., the ratio of IP
to IV blood AUC of %ID/g) is calculated to be 96% from the
fits to the blood data points in Figure 2B. The tumor accu-
mulations by IV and IP are therefore predicted to be essen-
tially the same by equation (4). Table 2a confirms this
prediction: 7.41% – 1.42%ID/g for the tumor of 0.38 – 0.18 g
by IP versus 6.51% – 0.65%ID/g for the tumor of 0.43 – 0.12 g
by IV. If corrected for influence of tumor size,19 the values
are essentially equal. Normal organ accumulations at 6 hours
FIG. 2. Radioactivity levels over time in cavity by IP (A) and in blood (B), lung (C), and kidneys (D) by IP and IV injections
of cMORF in normal mice. Note: the fluid volume in cavity is also included in A and the scales for IP and IV are different in B.
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are also similar with no statistically significant difference
(p > 0.05), although the averages seem slightly higher for IP in
most organs.
Absorbed radiation doses to blood, kidney,
and intestines
Three normal organs are of most interest for dosimetric
consideration20–24: blood, because bone marrow is very
radiosensitive; intestines, because they are also radiosen-
sitive and IP imposes much stronger radiation burden to
them than IV; and kidneys, because the radioactivity
clears through this organ exclusively. Tumor is the target,
but the doses are not listed (Table 2b) because they are
essentially the same due to the same accumulations be-
tween IV and IP.
The absorbed radiation doses listed in Table 2b are for
an injection of 100 lCi of 188Re or 90Y. Due to the 96%
bioavailability and therefore the essentially identical
blood AUC, the absorbed radiation doses to bone marrow
Table 2. Biodistribution of Radiolabeled cMORF (N = 4, Mean– SD) in Pretargeted Mice
and the Absorbed Radiation Doses to Organs of Interest
(a) %ID/g of 99mTc-cMORF at 6 hours in Mice Pretargeted 2 Days Earlier by MORF-CC49
Blood Liver Heart Kidney Lung Spleen Muscle Pancreas Tumor Tumor (g)
IV 1.43 – 0.24 0.83 – 0.14 0.32 – 0.05 4.66 – 0.64 0.50 – 0.12 0.38 – 0.05 0.14 – 0.02 0.23 – 0.02 6.51 – 0.65 0.43 – 0.12
IP 1.69 – 0.30 0.65 – 0.06 0.32 – 0.12 3.74 – 0.38 0.62 – 0.23 0.41 – 0.09 0.15 – 0.04 0.27 – 0.08 7.41 – 1.42 0.38 – 0.18
(b) Absorbed Radiation Doses for an Injection of 100lCi of 188Re- or 90Y-cMORFs
to Pretargeted Mice and the IP/IV Dose Ratios
Organ of interest Blood Intestines Kidneys
Re-188 IP (Rad) 3.1 82.6 81.6
IV (Rad) 3.5 2.5 95.1
IP/IV 0.89 33 0.86
Y-90 IP (Rad) 4.3 113 114
IV (Rad) 4.5 3.6 123
IP/IV 0.94 32 0.93
FIG. 3. Whole body images
of normal mice after IP or IV
injection of 99mTc-cMORF.
The maximum voxel
brightness for each is set such
that after decay correction it
is at the same value. Color
images available online at
www.liebertpub.com/cbr
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by IP and IV should be similar. For the intestines, the
absorbed radiation dose by IP calculated from the fits in
Fig. 4A is over 30-fold higher than that by IV. For kidneys,
dosimetric consideration requires the data of longer ob-
servation than that from the normal mouse study of this
investigation. As such, the required radioactivity data af-
ter 3 hours for IV and 6 hours for IP are derived from
previous pretargeting studies (Fig. 4B).9–11 To err on the
safe side, the 90Y curve was used. Due to the long reten-
tion, the doses are high and the difference between IV and
IP is small. Remarkably, the absorbed radiation dose to
intestines by IP has reached the dose level for this organ.
Discussion
In this report we clearly demonstrate that switching from
IV to IP can dramatically increase the absorbed radiation
dose to the intestines (actually the viscera in the cavity).
Under the conditions of this study, the calculated absorbed
radiation dose to the intestine has increased to a level com-
parable to that for the kidneys. Even this is likely to be an
underestimate, because the radioactivity is not evenly dis-
tributed within the peritoneal cavity but concentrates
between the viscera and immediately contacts with the in-
testinal walls. Therefore, the radiotoxicity observed in our
pilot study may be explained. In addition, although IP can
change the kinetics and dramatically increase the absorbed
radiation does in the cavity, as predicted, it does not reduce
the tumor accumulation if the bioavailability is not com-
promised.16,17
The dosimetric estimation is based on the clearance ki-
netics of free radiolabeled cMORF in mice. Therefore, similar
results should be expected for other directly radiolabeled
agents, if these agents leave the cavity similarly. At this
point, although no IP data by our method are available and
measuring them is beyond this investigation, the IP blood
curves in the literature should serve as a clue to whether
these agents leave the cavity similarly. The clearance rate of
a labeled agent from the blood can be very different but an
agent should lie in between two extremes: retaining in the
blood and rapid clearing from blood as schematically
shown in the Figure 5. The plateauing time in the first case
and the peak time in the latter are related to the cavity
absorption rate.
Most large molecules such as the radiolabeled antibodies
slowly clear from blood as shown in Figure 5A. The pla-
teauing time roughly represents the completion time of the
peritoneal absorption. For example, Costantini et al.3 re-
ported a plateauing time of 6.9 hours for a labeled antibody.
Compared with the labeled cMORF (about 4–6 hours, Fig. 2B),
FIG. 4. The total radioactivity for intestines by IV or IP (A) and the renal clearance curves after 4 hours with different
nuclides as labels (B).
FIG. 5. A schematic
showing the cavity and blood
levels after IP. injection of
rapid (A) and slow (B) blood-
clearing agents.
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antibodies seem to leave the cavity a little more slowly. Small
labeled molecules rapidly clear from blood unless they bind to
blood proteins. Their blood levels in mice peak at about 20–50
minutes, for examples: *20 minutes for the 18F-2-Fluoro-2-
Deoxy Glucose (18F-FDG),4*40 minutes for the 51Cr-ethylene-
diamine tetraacetic acid (51Cr-EDTA),25 and the*50 minutes
for the radiolabeled cMORF in this investigation. The com-
pletion of the cavity absorption may take longer than the
peak time, judged by the labeled cMORF (4–6 hours vs.*50
minutes).
Based on the limited information above, we speculate that
any radiotherapeutic agent after IP injection would impose
an absorbed radiation dose to the intestines (actually cavity
organs) at a level similar to that for the IP injection of the
labeled cMORF. If an agent itself has high normal organ
backgrounds, the increase of the cavity dose by IP compared
to that by IV may not seem dramatic. For example, many
labeled agents clear through liver into the intestines either
rapidly via the hepatobiliary path or slowly after taking up
by hepatocytes. The presence of radioactivity within the in-
testines following both IP and IV would make the ratio of IP
cavity dose to IV cavity dose smaller, but that would not
reduce the cavity dose induced by IP and the dose from the
radioactivity within the viscera would add its damaging ef-
fect. Another factor is the possibility of compromised bio-
availability following IP injection, as the 70% reported for a
labeled antibody.3 Apparently, any radioactivity left in the
cavity would also add its damage to the viscera in addition
to reducing tumor accumulation. The unanswered question
is whether the radiotoxicity induced by IP is dose-limiting.
For example, a recently published study with IP injection
reported the lethal dose of a 211At-labeled antibody induced
minimal damage to the intestinal histopathological structure,
suggesting that the death might be due to unknown toxici-
ty.25 At least, bone marrow toxicity has been known for a
long time to be an issue with radiolabeled antibodies.
In this investigation, we directly applied the kinetics of
cMORF to estimate the dosimetry for MORF/cMORF pre-
targeting, because the radiolabels11 and the pretargeting
antibody only minimally influenced the kinetics of free
cMORF. The low backgrounds and rapid renal clearance
characteristic of any qualified effector for pretargeting are
likely to suggest a very similar scenario with regard to the
dramatically increased absorbed radiation dose to the intes-
tines following IP injection. However, a direct extrapolation
is not possible due to the lack of IP data by our method at
this point.
Conclusion
Switching from IV injection to IP injection of labeled
cMORF dramatically increased the absorbed radiation dose
to intestines, although the bioavailability and tumor accu-
mulation was not compromised. This dramatic effect may
apply not only to pretargeting radiotherapy but also to
direct-targeting radiotherapy in common, especially for a
radiolabeled agent that rapidly clears from the circulation.
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